Nivolumab Enhances Survival in Resectable Lung Cancer: CheckMate 77T

‍ Updated June 11, 2025

Perioperative nivolumab (Opdivo; Bristol Myers Squibb) continues to demonstrate⁣ a significant, long-term benefit in event-free survival (EFS) and overall survival (OS) for patients with ⁤resectable non–small cell lung cancer (NSCLC), according to the phase 3 CheckMate 77T study. The findings, published in the Journal of Clinical Oncology and presented at the ⁤2025 American Society of Clinical ⁤Oncology (ASCO) annual Meeting, also revealed ⁣no new safety concerns.

The checkmate 77T trial,a randomized,double-blind study,involved adults with stage ⁢IIA to IIIB NSCLC. Participants received either neoadjuvant nivolumab plus chemotherapy or neoadjuvant ⁤chemotherapy plus placebo every three weeks for four cycles,followed ⁢by surgery and adjuvant nivolumab or placebo every four ⁣weeks for one year. The primary goal was to assess EFS.

After a median follow-up of 25.4 months, 70.2% of patients in the nivolumab group achieved 18-month EFS, compared to 50.0% in the chemotherapy group. The hazard ratio (HR) was 0.58. Pathological ⁣complete response (pCR) rate was also significantly higher in the nivolumab group (25.3%) versus the chemotherapy group (4.7%).

In an extended analysis with⁣ a median follow-up of 41.0 months, nivolumab maintained an EFS advantage compared to placebo, irrespective of PD-L1⁢ expression, tumor histology, or disease stage.‍ The hazard ratio was 0.61, with 30-month EFS rates of 61% and 43%, ⁢respectively. EFS from surgery also favored nivolumab in patients with or ⁢without pCR.

Biomarker analysis showed that patients with circulating tumor DNA (ctDNA) clearance, with or without pCR, experienced improved EFS. ‍Patients with specific tumor genomic alterations treated with nivolumab also showed‍ better EFS⁣ compared to those on placebo. Higher ctDNA clearance and ⁢pCR rates were observed in nivolumab-treated patients,regardless of mutation status.

Interim analysis‍ of overall survival (OS) indicated a ⁣trend toward improvement with nivolumab compared to placebo. The 30-month OS rates were 78% and 72%,‍ respectively, suggesting sustained OS benefits with nivolumab over a longer follow-up period.

Nivolumab, a fully human antibody against PD-1, combined with platinum-doublet chemotherapy, has become a standard neoadjuvant treatment for resectable NSCLC.Perioperative treatment‍ with nivolumab can further reduce the risk of relapse.Clinicians should evaluate patients for⁤ perioperative treatment feasibility and monitor thier⁤ response during nivolumab management.

What’s next

Further research will focus on identifying specific biomarkers to predict which patients will benefit most⁣ from perioperative nivolumab, potentially⁤ leading to more personalized treatment strategies for resectable NSCLC.